In 16 patients with cholangiocarcinoma who received gemcitabine as an adjuvant chemotherapy, there was no significant difference in relapse-free survival (P = 0.91; Figure 2D) or overall survival (P = 0.14; Figure 2E) according to KPNA2 expression. This evidence concerns the gene KPNA2 and cholangiocarcinoma.